Phase 1Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

About this study

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Enrolling at this location

Mayo Clinic in Arizona

Scottsdale, Arizona

I'm interested

This study also enrolls at 1 other location. See all.

Study details

Conditions

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant HistiocytosisPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPrimary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Follicular LymphomaRecurrent Langerhans Cell HistiocytosisRecurrent Lymphoplasmacytic LymphomaRecurrent Myelodysplastic SyndromeRecurrent MyelofibrosisRecurrent Small Lymphocytic LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory Chronic Lymphocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Erdheim-Chester DiseaseRefractory Follicular LymphomaRefractory Langerhans Cell HistiocytosisRefractory Lymphoplasmacytic LymphomaRefractory Myelodysplastic SyndromeRefractory MyelofibrosisRefractory Small Lymphocytic LymphomaRefractory Waldenstrom MacroglobulinemiaRosai-Dorfman-Destombes DiseasePrimary Central Nervous System LymphomaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Erdheim-Chester DiseaseRecurrent Fibroblastic Reticular Cell SarcomaRecurrent Histiocytic SarcomaRecurrent Interdigitating Dendritic Cell SarcomaRecurrent Rosai-Dorfman-Destombes DiseaseRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmRefractory Fibroblastic Reticular Cell SarcomaRefractory Histiocytic SarcomaRefractory Interdigitating Dendritic Cell SarcomaRefractory Rosai-Dorfman-Destombes Disease

Phase

Phase 1

Age

18 years and up

Gender

All genders welcome

Healthy volunteers

Not accepted

Last updated

Oct 2025

NCT ID

NCT06712810

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.